Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of rhBSSL vs Placebo in Preterm Infants Born Before 32 Weeks of Gestation
2010-023909-35Phase 3Completed
- Sponsor
- Sobi
- Start
- Mar 2011
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial comparing bucelipase alfa arm with placebo arm (2 arms). Primary endpoint: Growth velocity during 4 weeks of treatment. Started Mar 2011; status: completed.
02
Drugs
bucelipase alfa
Beyond the preview
Go deeper on 2010-023909-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023909-35.